Cart
sales@molnova.com
10-Hydroxycampothecin
CAS No. 67656-30-8
10-Hydroxycampothecin( 10-HCPT )
Catalog No. M19824 CAS No. 67656-30-8
10-Hydroxycamptothecin is a DNA topoisomerase I inhibitor utilized as a clinical therapy agent against hepatoma.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 221 | In Stock |
|
| 10MG | 319 | In Stock |
|
| 25MG | 492 | In Stock |
|
| 50MG | 761 | In Stock |
|
| 100MG | 1215 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name10-Hydroxycampothecin
-
NoteResearch use only, not for human use.
-
Brief Description10-Hydroxycamptothecin is a DNA topoisomerase I inhibitor utilized as a clinical therapy agent against hepatoma.
-
Description10-Hydroxycamptothecin is a DNA topoisomerase I inhibitor utilized as a clinical therapy agent against hepatoma.
-
In Vitro——
-
In Vivo——
-
Synonyms10-HCPT
-
PathwayCell Cycle/DNA Damage
-
TargetTopoisomerase
-
RecptorTopo I
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number67656-30-8
-
Formula Weight364.35
-
Molecular FormulaC20H16N2O5
-
Purity>98% (HPLC)
-
SolubilityDMSO:8 mg/mL (21.95 mM) warmed;Ethanol: Insoluble;Water: Insoluble
-
SMILESCCC1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Liu M et al. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance. J Drug Target. 2016;24(5):433-40.
molnova catalog
related products
-
Flumequine
Flumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat bacterial infections.
-
Voreloxin
A first-in-class anticancer quinolone derivative that intercalates DNA and inhibits Topoisomerase II.
-
DRF-1042
DRF-1042, an orally active camptothecin analog, exhibits anticancer and insecticidal activities by inhibiting DNA topoisomerase I. It has been studied for its efficacy against solid tumors, including prostate and colon cancers.
